Mariner LLC Trims Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Mariner LLC reduced its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 13.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,157 shares of the company’s stock after selling 1,667 shares during the period. Mariner LLC’s holdings in Dyne Therapeutics were worth $263,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DYN. KBC Group NV lifted its position in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the period. Summit Investment Advisors Inc. lifted its holdings in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after buying an additional 721 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $257,000. Magnetar Financial LLC purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $263,000. Finally, E Fund Management Co. Ltd. grew its holdings in Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after acquiring an additional 1,249 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 6,237 shares of company stock worth $77,760. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $11.83 on Tuesday. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45. The company has a market cap of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19. The stock’s 50 day simple moving average is $10.54 and its 200-day simple moving average is $18.59.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. JPMorgan Chase & Co. lowered their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Piper Sandler lowered their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Scotiabank began coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.46.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.